EXEL News and Press, Exelixis Inc. From 02/06/24

2024-02-06 20:45:15 ET Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q4 2023 Earnings Call Feb 06, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q4 2023 Earnings Call Transcript

2024-02-06 16:11:08 ET More on Exelixis Exelixis: 2024 Looking Good In The Mid-Term Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles Exelixis Q4 2023 Earnings Preview Exelixis forecasts 2024 revenue between $1.83B - $1.93B Se...

- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 - - Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 - ...

Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...

2024-02-05 17:05:44 ET More on Exelixis Exelixis: 2024 Looking Good In The Mid-Term Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles Exelixis forecasts 2024 revenue between $1.83B - $1.93B Read the full article on Seeking Alpha ...

2024-02-04 12:00:49 ET More on AbbVie, Johnson & Johnson, etc. AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript Merck & Co., Inc. 2023 Q4 - Results - Earnings Call Presentation Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript AbbVie cit...

– Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer – – Findings to be presented during an oral presentation at ASCO GU 2024 – ...

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2023 financial results will be released on Tuesday, February 6, 2024 after the markets close. At 5:00 p.m. ET ...

Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib Four-year results demonstrating continued benefits with immunotherapy-tyrosine kinase inhibitor combination to be shared in an oral presen...

Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposit...